# An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

> **NCT02213926** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 124 (actual)

## Conditions studied

- Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** ACP-196 (acalabrutinib)

## Key facts

- **NCT ID:** NCT02213926
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-03-02
- **Primary completion:** 2020-12-04
- **Final completion:** 2026-09-06
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02213926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02213926, "An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT02213926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*